Byetta
Sep 12, 2009 at 08:16 | Source: Business Line
Jul 28, 2006 at 18:02
Photos »
/ 
News across the web »
Mar 29, 2012 at 04:17 | Source: Market Watch
Jan 28, 2012 at 07:37 | Source: Market Watch
Jan 28, 2012 at 04:31 | Source: Forbes
Jan 28, 2012 at 03:42 | Source: Market Watch
Related News »
Offers were due yesterday for the San Diego-based company, whose medicines include Bydureon and Byetta, the people said. Takeda Pharmaceutical Co. and Bristol-Myers Squibb Co. (BMY) indicated to Amylin they also would make bids, the people said.
May 26, 2012 at 06:01 | Source: Bloomberg
The Company is marketing two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. The full research report on Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is available here: www.BrightonMarkets.com ...
May 25, 2012 at 12:57 | Source: msnbc.com
First-round bids are due in the next two weeks, said two of the people. Amylin, the maker of the diabetes drugs Bydureon and Byetta, has a market capitalization of more than $4 billion and generated more than $650 million in revenue (AMLN) ...
May 14, 2012 at 23:55 | Source: Businessweek
Although this may raise valid questions about the long-term profitability of the Byetta-to-Bydureon switch among the bear camp, compared to the M&A buzz it's like holding a match next to a stadium floodlight. Along similar lines, I wonder if the potential ...
May 16, 2012 at 06:06 | Source: Seekingalpha.com
The drugmaker is interested in buying San Diego-based Amylin Pharmaceuticals Inc. (AMLN) and its diabetes drugs Bydureon and Byetta, which generated more than $650 million in revenue last year, Bloomberg reported on May 15. Warner Chilcott Plc ...
May 18, 2012 at 11:11 | Source: Bloomberg
Also known by the trade name Byetta, exenatide was approved by the Food and Drug Administration in April 2005 to help manage blood sugar levels in individuals who have type 2 diabetes. Now, at Sahlgrenska Academy, University of Gothenburg, investigators ...
May 18, 2012 at 10:28 | Source: eMaxHealth.com
Amylin, which makes diabetes drugs Bydureon and Byetta, rejected a $3.9 billion offer from Bristol-Myers Squibb, which prompted a suit from investor Carl Icahn. Icahn has since withdrawn the suit, but encouraged a sale of the company. Now, according to ...
May 16, 2012 at 09:55 | Source: Philadelphia Daily News
Earlier in the year, Amylin received FDA approval for Bydureon, a once-weekly version of the injectable diabetes medication Byetta, which has been available in the U.S. since June 2005. In March, Amylin rejected a $3.5 billion unsolicited ...
May 23, 2012 at 10:51 | Source: NASDAQ
The companys products include BYETTA (exenatide) injection for the treatment of type 2 diabetes; and SYMLIN (pramlintide acetate) injection for the treatment of type 1 and type 2 diabetes. It also has research and development (R&D) programs in ...
May 23, 2012 at 15:23 | Source: TMCnet
Assess physicians' opinions of Bydureon as compared with Amylin's twice-daily Byetta (exenatide) and Novo Nordisk's once-daily Victoza (liraglutide) - Determine physicians' expectations for Bydureon's uptake, line of therapy, and use in combination with other antidiabetics
May 14, 2012 at 06:44 | Source: Transworld News